Dylan Dupuis

As Novavax, Inc. (NASDAQ: NVAX) approaches two key dates in its pipeline, bulls are preparing to profit. The Rating B Riley FBR analysts George Zavoico and Dylan Dupuis maintained a Buy rating on Novavax with a $10 price target. The Thesis The biotech will complete two clinical trials in the first...